ilmscore | Prediction Details
"I do believe that with the uh with the compound restrictions with the pill form coming out as well as just with more indications being approved for Reggoi like we saw with that fatty liver disease I believe this is going to be upgraded"
By Let's Talk Money! with Joseph Hogue, CFA | August 19, 2025 | Pending
From video
Buy Heavy! This is How I Found the Next 158% Stock 00:10:32 - 00:10:46
Interpreted Prediction
Novo Nordisk's 2025 sales growth forecast (currently 8-14%) is predicted to be upgraded due to increased restrictions on compounded drugs, the release of the pill form, and new indications for Wegovy.

Prediction Details

Ticker
NVO
Initial Price
54.78 USD

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.